ライフサイエンスコーパス: emesis

1 ects on PDE4B (anti-inflammatory) and PDE4D (emesis).

2 g nonrespiratory responses (e.g. coughing or emesis).

3 stance P antagonist for chemotherapy-induced emesis.

4 ties included flu-like symptoms, nausea, and emesis.

5 ethasone for prevention of acute and delayed emesis.

6 MK-869 plus dexamethasone in reducing acute emesis.

7 methasone provided the best control of acute emesis.

8 d 10(10) CFU experienced watery diarrhea and emesis.

9 and another experienced a single episode of emesis.

10 catharsis and emesis and from vomitus during emesis.

11 itors cannot be used in humans due to severe emesis.

12 xamethasone improves the prevention of acute emesis.

13 bserved prevention rate or delay the time to emesis.

14 the two-dose regimen in those patients with emesis.

15 of glucoregulation, weight loss, nausea, and emesis.

16 ng appetite and food consumption and causing emesis.

17 y adverse side effects, including nausea and emesis.

18 ucoregulatory GLP-1RA devoid of anorexia and emesis.

19 nd type 2 diabetes, ideally devoid of nausea/emesis.

20 nge, and reduced viral shedding in stool and emesis.

21 sma drug levels without associated nausea or emesis.

22 nts receiving the same prophylaxis for acute emesis.

23 efficacy and toxicity in preventing delayed emesis.

24 been hampered by their major side effect of emesis.

25 pus enhances memory but appears not to cause emesis.

26 f nausea, which is not as well controlled as emesis.

27 e salivation, or physiological correlates of emesis.

28 rapeutic benefits without inducing nausea or emesis.

29 5 mg/kg, no injections completely eliminated emesis.

30 rease) in correlation with cisplatin-induced emesis.

31 s alternative models of chemotherapy-induced emesis.

32 s physiological roles in control of pain and emesis.

33 inal pain/nausea/dehydration and grade 4 AST/emesis.

34 postoperative pain and reduced postoperative emesis.

35 is recommended for the prevention of delayed emesis.

36 ethasone to protect one patient from delayed emesis.

37 after chemotherapy for prevention of delayed emesis.

38 %), anemia (13%), diarrhea (22%), and nausea/emesis (11%) in both study arms.

39 4 toxicities included diarrhea (38%), nausea/emesis (19%), fatigue (16%), dehydration (16%), and derm

40 4%), grade 3 fatigue (14.3%), grade 3 nausea/emesis (22%), grade 3 diarrhea (10%), and grade 3 mucosi

41 s presented fever (74.7%), asthenia (67.7%), emesis (38.2%), diarrhea (28.3%), and hemorrhage (11.8%)

42 toclopramide [P = .023]) but not episodes of emesis (5.0 [SD, 3.1] vs 3.3 [SD, 3], respectively [P =

43 R, 2.37; 95% CI, 1.09 to 5.15; P = .026) and emesis (78% v 65%; OR, 1.99; 95% CI, 1.25 to 3.18; P = .

44 c modulators have reduced potential to cause emesis, a dose-limiting side effect of existing active s

45 dexamethasone for the prevention of delayed emesis after chemotherapeutic agents of high emetic risk

46 ethasone for prevention of acute and delayed emesis after high-dose cisplatin.

47 ceptor antagonist L-754,030 prevents delayed emesis after treatment with cisplatin.

48 nd diarrhea were more common with erlotinib; emesis, alopecia, peripheral neuropathy, and fatigue wer

49 Operating time, postoperative emesis, analgesia requirements, time to full feeding, le

50 l tolerated; the principal side effects were emesis and a transient decrease in blood pressure.

51 polypeptide receptor (GIPR) signaling blocks emesis and attenuates illness behaviors elicited by GLP-

52 in rats and shrews that GIPR agonism blocks emesis and attenuates other malaise behaviors elicited b

53 an alleviate chemotherapy-induced nausea and emesis and chronic pain.

54 ts that are relevant to clinical efficacy in emesis and depression.

55 ir, or saliva before and after catharsis and emesis and from vomitus during emesis.

56 The main risk factors are postoperative emesis and intraoperative extensive photocoagulation.

57 onergic system, such as chemotherapy-induced emesis and irritable bowel syndrome.

58 to 4 hours of food ingestion with repetitive emesis and lethargy.

59 ebo in controlling cisplatin-induced delayed emesis and may provide additive benefit in acute emesis

60 of MK-869 was effective in reducing delayed emesis and nausea after high-dose cisplatin.

61 is and may provide additive benefit in acute emesis and nausea control when combined with a 5-hydroxy

62 ects of apomorphine treatment include severe emesis and nausea, and ulceration and pain at the inject

63 benefits, but adverse effects, in particular emesis and nausea, have curbed their clinical utility.

64 that it may represent a useful correlate of emesis and nausea.

65 Ten (83%) patients had dyspnoea, fever, and emesis and nine (75%) had cough.

66 ated with higher complete response rates (no emesis and no rescue medications) compared with palonose

67 point (complete response) was defined as no emesis and no rescue therapy within 120 hours of melphal

68 primary end point was complete response (no emesis and no rescue therapy) on days 1 to 5 postcisplat

69 e primary end point; a complete response (no emesis and no use of rescue medication) was a secondary

70 N, and PBN are associated with activation of emesis and perhaps nausea.

71 produced vomiting only, GR73632 caused both emesis and scratching behavior dose-dependently in shrew

72 of GR73632 to induce a maximal frequency of emesis and shifted its percent animals vomiting dose-res

73 expiratory muscles during behaviors such as emesis and some postural adjustments can be elicited thr

74 well as incidence and severity of nausea and emesis and use of antiemetic rescue medication.

75 ghty-eight percent had hematochezia, 63% had emesis, and 33% had intermittent diarrhea before surgery

76 virus administration were flu-like symptoms, emesis, and abdominal pain.

77 Nausea, emesis, and anorexia are common features of these disord

78 actor 15 (GDF15) is a contributor to nausea, emesis, and anorexia following chemotherapy via binding

79 disorders are often associated with nausea, emesis, and anorexia.

80 ntly higher probability of CR, no nausea, no emesis, and complete protection (81.0%, 63.7%, 95.4%, an

81 hat more neutropenia, elevations in AST/ALT, emesis, and fatigue occurred in the q3 weeks 24-hour, th

82 , fever, headache, abdominal pain, diarrhea, emesis, and fatigue) with symptoms of other more common

83 department for a frontal headache, eye pain, emesis, and lethargy.

84 Patients had nausea, emesis, and obtundation.

85 ased the incidence of postreinfusion nausea, emesis, and oxygen desaturation in comparison to unselec

86 were noted in 5/6 pigs including diarrhoea, emesis, and skin rash.

87 ipheral pain, migraine, chemotherapy-induced emesis, and various psychiatric disorders.

88 not significantly improve control of delayed emesis as compared with dexamethasone monotherapy (ARR,

89 (LES) is critical for normal swallowing and emesis, as well as for the prevention of gastroesophagea

90 sted as gastrointestinal stasis, nausea, and emesis associated with illness.

91 hibitor with low oral bioavailability and no emesis-associated behaviors in ferrets at plasma concent

92 eduction in emetic side effects (ferret, 20% emesis at 30 mg/kg, po).

93 Although SSP-SAP injection reduced emesis at GR73632 doses of 2.5 and 5 mg/kg, no injection

94 nism-related side effects such as nausea and emesis at high doses.

95 f side effects such as ataxia, sedation, and emesis at this dose.

96 ve for preventing acute chemotherapy-induced emesis but the benefits of continuing administration of

97 ommodate food during ingestion and preceding emesis, but has quite different functions from the antru

98 marketed for prevention of vagally-mediated emesis caused by cancer chemotherapeutic agents.

99 ninergic system is not well-characterized in emesis-competent species.

100 s, chest and abdominal pain, nausea, bilious emesis, cough, and shortness of breath.

101 indicates that acupuncture is effective for emesis developing after surgery or chemotherapy in adult

102 ng the same antiemetic prophylaxis for acute emesis, dexamethasone was not superior to aprepitant but

103 adverse gastrointestinal symptoms, including emesis, diarrhea, abdominal cramping, and gastrointestin

104 mon toxicities included pain, fever, nausea, emesis, diarrhea, urticaria, mild elevation of hepatic t

105 rtment with a 1-week history of intermittent emesis, dizziness, and vertigo and a 1-day history of wo

106 rtment with a 1-week history of intermittent emesis, dizziness, and vertigo and a 1-day history of wo

107 udy was the proportion of patients free from emesis during the study period.

108 of this combination included fever, nausea, emesis, electrolyte imbalance, and fluid retention that

109 percentage of patients who developed delayed emesis (emesis on the second to fifth days after cisplat

110 There were significantly fewer number of emesis episodes and doses of analgesia given in the lapa

111 The number of emesis episodes occurring during the 5 days was lower fo

112 Complete control of emesis (expressed as the percentage of patients who had

113 Nausea, emesis, fatigue, dehydration, and hyponatremia also were

114 assessed by modified Functional Living Index-Emesis (FLIE) questionnaire on days -1 and 6.

115 in the shrew demonstrated a near absence of emesis for GEP44 in contrast to Ex-4.

116 The proportion of nausea- and emesis-free patients at 24 and 48 hours were also approx

117 id hyperemesis syndrome (CHS), ie, recurrent emesis from chronic cannabis use, is increasingly observ

118 Saliva before and after emesis grew low quantities of H pylori in 3 (18.8%) and

119 dies on the etiology of chemotherapy-related emesis have implicated brainstem nuclei and the neurotra

120 xicities included fatigue, nausea, diarrhea, emesis, headache, rash/pruritus, increased AST/ALT, and

121 r toxicities have been documented, including emesis, hypersensitivity reactions, cardiovascular event

122 oncerned with neuro-otology, pharmacology of emesis, imaging, cochlear prostheses and aspects of vert

123 hasone 20 mg given only once prevented acute emesis in 76% of patients who received cisplatin > or =

124 Highly emetogenic chemotherapy induces emesis in almost all patients in the absence of prophyla

125 nd oral dexamethasone 20 mg to prevent acute emesis in cancer patients receiving initial cisplatin at

126 central opioids may induce APCs and prevent emesis in conscious dogs.

127 t, at 5 mg/kg it failed to cause significant emesis in either phase, while its 20 mg/kg dose induced

128 d period, the proportion of patients without emesis in groups I, II, III, and IV was 29%, 63%, 51%, a

129 , 80%, 46%, and 43% of patients were without emesis in groups I, II, III, and IV, respectively (P <.0

130 Although compound 2 produces emesis in humans when given as a single dose, its exempl

131 ent visit, prophylaxis for acute and delayed emesis in patients receiving moderate to highly emetic c

132 superior to aprepitant in preventing delayed emesis in patients receiving the same prophylaxis for ac

133 Only SEC1 induced emesis in the monkey feeding assay.

134 ica behavior, a proxy for nausea in rats, or emesis in the musk shrew, a vomiting mammalian model.

135 Drug-related grade 3 toxicity included emesis, increased ALT, hypersensitivity reactions (two p

136 nded for the prophylaxis of acute or delayed emesis induced by chemotherapy containing anthracyclines

137 ifferent computational tools against various emesis-inducing receptors (D(2), D(3), 5HT(3), H(1), and

138 les in depression, anxiety, substance abuse, emesis, inflammatory pain, spinal nociception, gastroint

139 The induction of nausea and emesis is a major barrier to maximizing the weight loss

140 es of agents affecting receptors involved in emesis is necessary to effectively treat PONV.

141 tion of acute childhood poisonings for which emesis is not contraindicated.

142 ggest that acupuncture may reduce nausea and emesis, it is unclear whether such benefit comes from th

143 D-specific inhibitor Gebr32a did not trigger emesis-like side effects in rodents.

144 hemotherapy poses considerable challenges to emesis management.

145 -mediated anesthesia, a surrogate measure of emesis, miRNA-mediated PDE4D knock-down in the hippocamp

146 ogues were found to be nonemetic in a canine emesis model at intravenous doses of up to 3 mg/kg.

147 st shrew appears to be a sensitive and rapid emesis model for both phases of CIV, and both emetic pha

148 s in humans and least shrews, a small animal emesis model which also vomits in response to substance

149 n to further establish Cryptotis parva as an emesis model, by sequencing and characterizing SP mRNA,

150 e evaluated the new compounds in a surrogate emesis model, showing nonemetic effects.

151 se of general anxiety (n = 5), nausea and/or emesis (n = 2), or asymptomatic occlusion of an external

152 onhematologic toxicities included nausea and emesis, neuropathy, and arthralgia/myalgia.

153 ary efficacy end point was total control (no emesis, no nausea, and no use of antiemetic rescue medic

154 imary endpoint was complete response (CR: no emesis/no rescue medication) during the overall phase (0

155 platin, we evaluated the prevention of acute emesis (occurring within 24 hours) and delayed emesis (o

156 d Relevance: For mild symptoms of nausea and emesis of pregnancy, ginger, pyridoxine, antihistamines,

157 ge of patients who developed delayed emesis (emesis on the second to fifth days after cisplatin).

158 esis (occurring within 24 hours) and delayed emesis (on days 2 to 5) after a single dose of cisplatin

159 The presence or absence of posttussive emesis or inspiratory whoop modestly change the likeliho

160 Additional medication was available to treat emesis or nausea at any time.

161 f patients achieving a complete response (no emesis or use of rescue medication) in the delayed phase

162 achieving a complete response (defined as no emesis or use of rescue medication) in the delayed phase

163 al girth, distension, subjective discomfort, emesis, or diarrhea.

164 ng was not essential for T cell stimulation, emesis, or lethality although in general the mutants wer

165 models of central nervous system behaviors, emesis, or nausea.

166 no nausea, score of Functional Living Index-Emesis; P < .24).

167 nt clinical features of FPIES are repetitive emesis, pallor, and lethargy; chronic FPIES can lead to

168 The median nausea score in the delayed-emesis phase was significantly lower in group 1 than in

169 In the delayed-emesis phase, 82 percent of the patients in group 1, 78

170 In the acute-emesis phase, 93 percent of the patients in groups 1 and

171 e photocoagulation (OR, 4.94; P < .001), and emesis postoperatively (OR, 24.39; P < .001).

172 rs of delayed suprachoroidal hemorrhage were emesis postoperatively (P < .001) and extensive intraope

173 There was no observed difference in emesis prevention between the one-dose (76%) and two-dos

174 vention of acute (0 to 24 hours) and delayed emesis (primary efficacy parameter; days 2 to 5) after c

175 ation of peripheral NK1 receptors can affect emesis produced by GR73632.

176 As yet, no study has confirmed that emesis produced by SP or a selective NK1 receptor agonis

177 nausea scale on the Functional Living Index-Emesis quality-of-life questionnaire.

178 ticosteroids vs metoclopramide was reported (emesis reduction, 40.9% vs 16.5% at day 2; 71.6% vs 51.2

179 l grey, trigeminal nuclei, dorsal raphe, and emesis-related brainstem nuclei including the area postr

180 beyond 24 hours after chemotherapy (delayed emesis) remain unclear.

181 C. parva as a model organism, especially for emesis research.

182 plus at least one of the following symptoms: emesis, rigors, hypotension, or flank pain.

183 r plus at least 1 of the following symptoms: emesis, rigors, hypotension, or flank pain.

184 to investigate virus recovery from stool and emesis samples using HBGA-coated beads.

185 Presence of posttussive emesis (summary likelihood ratio [LR], 1.8; 95% confiden

186 y LR, 0.52; 95% CI, 0.27-1.0) or posttussive emesis (summary LR, 0.58; 95% CI, 0.44-0.77) reduced the

187 cupuncture was more effective in controlling emesis than minimal needling or antiemetic pharmacothera

188 minimal needling group had fewer episodes of emesis than the antiemetic pharmacotherapy alone group (

189 ectroacupuncture group had fewer episodes of emesis than the minimal needling group (P<.001), whereas

190 component in neurokinin NK-receptor mediated emesis, the authors undertook this study to examine the

191 of overlapping and interrelated problems of emesis, vertigo and migraine which promises an early sol

192 P (SP) is thought to play a cardinal role in emesis via the activation of central tachykinin NK1 rece

193 The median time to the onset of emesis was 19 hours for the one-dose regimen and 17 hour

194 The rate of complete control of emesis was 61.2% in the granisetron group and 67.1% in t

195 Emesis was associated with 10.5 g SNAC.

196 sed as the percentage of patients who had no emesis) was as follows: day 1, 85.7% (group 1) and 66.7%

197 phageal intubation with delayed recognition, emesis with aspiration, hypotension requiring interventi

198 kg dose of cisplatin produced both phases of emesis with corresponding peak mean frequencies occurrin

199 namic tracheal intubation-associated events, emesis with/without aspiration) and/or oxygen desaturati

200 e acute [< or = 24 hours after chemotherapy] emesis without antiemetic prophylaxis); level 2 (10% to